Related papers: Bayesian modelling of response to therapy and drug…
Acute Lymphoblastic Leukemia (ALL) is one of the most common types of childhood blood cancer. The quick start of the treatment process is critical to saving the patient's life, and for this reason, early diagnosis of this disease is…
Acute Lymphoblastic Leukemia (ALL) accounts for the 80% of leukemias when coming down to pediatric ages. Survival of these patients has increased by a considerable amount in recent years. However, around 15-20% of treatments are…
Acute Lymphoblastic Leukemia (ALL) is the most frequent hematologic malignancy in children and adolescents. A strong prognostic factor in ALL is given by the Minimal Residual Disease (MRD), which is a measure for the number of leukemic…
Acute lymphoblastic leukemia is the most frequent pediatric cancer. Approximately two third of survivors develop one or more health complications known as late adverse effects following their treatments. The existing measures offered to…
Acute Myeloid Leukemia (AML) is a highly aggressive blood cancer with low survival rates. Hence, emphasizing the importance of the urgent need for effective treatment modalities. In recent times, the advances in cancer genomics have…
Acute lymphoblastic leukemia (ALL) is the most malignant form of leukemia and the most common cancer in adults and children. Traditionally, leukemia is diagnosed by analyzing blood and bone marrow smears under a microscope, with additional…
Acute lymphoblastic leukemia (ALL) is a form of blood cancer that affects the white blood cells. ALL constitutes approximately 25% of pediatric cancers. Early diagnosis and treatment of ALL are crucial for improving patient outcomes. The…
This research paper focuses on Acute Lymphoblastic Leukemia (ALL), a form of blood cancer prevalent in children and teenagers, characterized by the rapid proliferation of immature white blood cells (WBCs). These atypical cells can overwhelm…
We present a reproducible deep learning pipeline for leukemic cell classification, focusing on system architecture, experimental robustness, and software design choices for medical image analysis. Acute lymphoblastic leukemia (ALL) is the…
Novel dose-finding designs, using estimation to assign the best estimated maximum- tolerated-dose (MTD) at each point in the experiment, most commonly via Bayesian techniques, have recently entered large-scale implementation in Phase I…
Our motivation stems from current medical research aiming at personalized treatment using a molecular-based approach. The broad goal is to develop a more precise and targeted decision making process, relative to traditional treatments based…
Acute lymphoblastic leukemia is the most common malignancy in childhood. Successful treatment requires initial high-intensity chemotherapy, followed by low-intensity oral maintenance therapy with oral 6-mercaptopurine (6MP) and methotrexate…
Model-informed precision dosing (MIPD) using therapeutic drug/biomarker monitoring offers the opportunity to significantly improve the efficacy and safety of drug therapies. Current strategies comprise model-informed dosing tables or are…
Acute lymphoblastic leukaemia (ALL) is a blood malignancy that mainly affects adults and children. This study looks into the use of deep learning, specifically Convolutional Neural Networks (CNNs), for the detection and classification of…
Background. Alzheimer's disease and related dementia (ADRD) are characterized by multiple and progressive anatomo clinical changes. Yet, modeling changes over disease course from cohort data is challenging as the usual timescales are…
Acute lymphoblastic leukemia (ALL) severity is determined by the presence and ratios of blast cells (abnormal white blood cells) in both bone marrow and peripheral blood. Manual diagnosis of this disease is a tedious and time-consuming…
An accurately identified maximum tolerated dose (MTD) serves as the cornerstone of successful subsequent phases in oncology drug development. Bayesian logistic regression model (BLRM) is a popular and versatile model-based dose-finding…
Thousands of individuals succumb annually to leukemia alone. As artificial intelligence-driven technologies continue to evolve and advance, the question of their applicability and reliability remains unresolved. This study aims to utilize…
Traditional health authority approval for oncology drugs is based on a clinical benefit endpoint, or a valid surrogate. In 1992 the FDA created the Accelerated Approval pathway to allow for earlier approval of therapies in serious…
With the application of hematopoietic stem cell transplantation and new drugs, the progression-free survival rate and overall survival rate of multiple myeloma have been greatly improved, but it is still considered as a kind of disease that…